Literature DB >> 35175325

Treating CAR-T relapses: check not checkmate.

Jay Y Spiegel1, Krishna V Komanduri1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35175325      PMCID: PMC8854681          DOI: 10.1182/blood.2021013896

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

Review 2.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 3.  Tumor Antigen Escape from CAR T-cell Therapy.

Authors:  Robbie G Majzner; Crystal L Mackall
Journal:  Cancer Discov       Date:  2018-08-22       Impact factor: 39.397

4.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

5.  Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Authors:  Frederick L Locke; John M Rossi; Sattva S Neelapu; Caron A Jacobson; David B Miklos; Armin Ghobadi; Olalekan O Oluwole; Patrick M Reagan; Lazaros J Lekakis; Yi Lin; Marika Sherman; Marc Better; William Y Go; Jeffrey S Wiezorek; Allen Xue; Adrian Bot
Journal:  Blood Adv       Date:  2020-10-13

6.  Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.

Authors:  Elise A Chong; Cécile Alanio; Jakub Svoboda; Sunita D Nasta; Daniel J Landsburg; Simon F Lacey; Marco Ruella; Siddharth Bhattacharyya; E John Wherry; Stephen J Schuster
Journal:  Blood       Date:  2022-02-17       Impact factor: 25.476

7.  Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.

Authors:  Jay Y Spiegel; Saurabh Dahiya; Michael D Jain; John Tamaresis; Loretta J Nastoupil; Miriam T Jacobs; Armin Ghobadi; Yi Lin; Matthew Lunning; Lazaros Lekakis; Patrick Reagan; Olalekan Oluwole; Joseph McGuirk; Abhinav Deol; Andre Goy; Khoan Vu; Charalambos Andreadis; Javier Munoz; N Nora Bennani; Julie M Vose; Kathleen A Dorritie; Sattva S Neelapu; Frederick L Locke; Aaron P Rapoport; Brian T Hill; David B Miklos
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113

8.  Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.

Authors:  Michael D Jain; Hua Zhao; Xuefeng Wang; Reginald Atkins; Meghan Menges; Kayla Reid; Kristen Spitler; Rawan Faramand; Christina Bachmeier; Erin A Dean; Biwei Cao; Julio C Chavez; Bijal Shah; Aleksandr Lazaryan; Taiga Nishihori; Mohammed Hussaini; Ricardo J Gonzalez; John E Mullinax; Paulo C Rodriguez; Jose R Conejo-Garcia; Claudio Anasetti; Marco L Davila; Frederick L Locke
Journal:  Blood       Date:  2021-05-13       Impact factor: 25.476

9.  Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.

Authors:  Kevin R Parker; Elena Sotillo; Evan W Weber; Rachel C Lynn; Hima Anbunathan; John Lattin; Zinaida Good; Julia A Belk; Bence Daniel; Dorota Klysz; Meena Malipatlolla; Peng Xu; Malek Bashti; Sabine Heitzeneder; Louai Labanieh; Panayiotis Vandris; Robbie G Majzner; Yanyan Qi; Katalin Sandor; Ling-Chun Chen; Snehit Prabhu; Andrew J Gentles; Thomas J Wandless; Ansuman T Satpathy; Howard Y Chang; Crystal L Mackall
Journal:  Science       Date:  2021-04-02       Impact factor: 47.728

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.